ArticleLeukemia2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus.Veterinary sciences · 2023Article
- Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States.Cells · 2022Article
- Impaired JAK-STAT pathway signaling in leukocytes of the frail elderly.Immunity & ageing : I & A · 2022Article
- COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.Cytokine & growth factor reviews · 2021Review
- Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.Clinical microbiology reviews · 2021Review
- TextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora.Proceedings of the conference. Association for Computational Linguistics. North American Chapter. Meeting · 2021Article
- COVID-19 vaccines: The status and perspectives in delivery points of view.Advanced drug delivery reviews · 2021Review
- COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options.Infectious diseases and therapy · 2021Review
- Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.Biomolecules · 2021Review
- Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.Frontiers in pharmacology · 2021Article
- Potential therapeutic and pharmacological strategies for SARS-CoV2.Journal of pharmaceutical investigation · 2021Review
- Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients.Frontiers in aging · 2021Review
- Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?Frontiers in physiology · 2020Review
- COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.